Imagine if you could detect a hidden health issue without needing surgery. This technology listens to the electrical signals of the uterus, similar to how a heart monitor works, to find signs of endometriosis. It replaces the need for invasive operations just to get a diagnosis. This means women can get help years sooner without the risks of general anesthesia.
Endometriosis diagnosis currently relies on invasive surgery, leading to a 7-12 year delay in treatment and high healthcare costs. Many patients are misdiagnosed or overlooked due to the lack of a simple, non-invasive testing method.
A non-invasive diagnostic test based on a digital biomarker derived from uterine electromyogram (EMG) signal processing.
If you are a diagnostic equipment manufacturer dealing with the high cost and risk of surgical laparoscopy — this project developed a digital biomarker test that enables simpler and more cost-effective diagnosis.
If you are a private clinic dealing with the 7 to 12 year delay in diagnosing patients — this project developed a non-invasive test that allows for earlier detection and informed medical decisions.
If you are a health-tech developer dealing with the lack of objective data for chronic inflammatory diseases — this project developed signal processing for a uterine electromyogram that creates a validated digital biomarker.
It replaces the current gold standard, laparoscopy, which requires an expensive operative procedure under general anesthesia, with a non-invasive digital test.
Based on available project data, the target market is significant as at least 190 million women and adolescent girls worldwide are affected by the disease.
Based on available project data, the project focuses on maturing the technology to investor readiness and validating the biomarker in a clinical setting, but specific patent details are not listed.
The project period is from 2023-01-01 to 2025-12-31, with the end point being the evaluation of data from a prospective clinical study.
The test is designed to be a simpler, non-invasive alternative that prevents the trivialization of symptoms at the GP level and avoids the 7-12 year diagnostic delay.
The project is led by a single SME, Onawave Medical Limited, based in Ireland. With a 100% industry ratio and a single partner, the project is streamlined for commercial agility and is focused on moving a specific technology from a research prototype to investor readiness.
Contact Onawave Medical Limited in Ireland regarding the She Sense diagnostic test.
Contact us to find licensing opportunities for this digital biomarker.
